Yıl: 2022 Cilt: 38 Sayı: 3 Sayfa Aralığı: 213 - 218 Metin Dili: İngilizce DOI: 10.5146/tjpath.2021.01565 İndeks Tarihi: 08-10-2022

Methylation Profiling of Specific Genes in Ependymomas

Öz:
Objective: Ependymomas are neuroepithelial tumors of the central nervous system with heterogeneous biology and clinical course. The aim of the present study is to investigate the relationship between the methylation status and clinicopathological parameters in ependymomas. Material and Method: DNA methylation status of CDKN2A, RASSF1A, KLF4 and ZIC2 genes were quantitatively analyzed with pyrosequencing in 44 ependymoma tumor tissues. The relationship of methylation profiles with tumor subtype, histological grade and patient age was statistically analyzed. Results: DNA methylation analyses for CDKN2A revealed no difference in methylation levels. Of the 31 included samples for optimal ZIC2 methylation analysis, 10 were hypermethylated (32.3%) and this change was significantly found in the adult spinal ependymomas (p=0.01). KLF4 hypermethylation was observed in 6 of the overall included 35 samples (17.1%); however, there was no statistically significant relation of the methylation status with tumor subtype, histological grade or age group. RASSF1A hypermethylation was observed in overall 40 included samples with varying methylation levels. Higher levels of hypermethylation were significantly related to the grade 3 histology (p=0.01) and spinal ependymomas (p=0.006). The pediatric cases with grade 3 ependymomas and ependymomas of adulthood showed significantly increased RASSF1A hypermethylation levels (p<0.001 and p=0.001, respectively). Conclusion: DNA methylation changes are likely to have biological importance in ependymomas. Both ZIC2 and RASSF1A methylation status may be useful parameters in the subclassification of these tumors.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
0
0
0
  • 1. Korshunov A, Witt H, Hielscher T, Benner A, Remke M, Ryzhova M, Milde T, Bender S, Wittmann A, Schöttler A, Kulozik AE, Witt O, von Deimling A, Lichter P, Pfister S. Molecular staging of intracranial ependymoma in children and adults. J Clin Oncol. 2010;28:3182-90.
  • 2. Gatta G, Botta L, Rossi S, Aareleid T, Bielska-Lasota M, Clavel J, Dimitrova N, Jakab Z, Kaatsch P, Lacour B, Mallone S, Marcos- Gragera R, Minicozzi P, Sánchez-Pérez MJ, Sant M, Santaquilani M, Stiller C, Tavilla A, Trama A, Visser O, Peris-Bonet R; EUROCARE Working Group. Childhood cancer survival in Europe 1999-2007: Results of EUROCARE-5-a population-based study. Lancet Oncol. 2014;15:35-47.
  • 3. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW. The 2021 WHO classification of tumors of the central nervous system: A summary. Neuro Oncol 2021;23:1231-51.
  • 4. Neumann JE, Spohn M, Obrecht D, Mynarek M, Thomas C, Hasselblatt M, Dorostkar MM, Wefers AK, Frank S, Monoranu CM, Koch A, Witt H, Kool M, Pajtler KW, Rutkowski S, Glatzel M, Schüller U. Molecular characterization of histopathological ependymoma variants. Acta Neuropathol. 2020;139:305-18.
  • 5. Pajtler KW, Witt H, Sill M, Jones DT, Hovestadt V, Kratochwil F, Wani K, Tatevossian R, Punchihewa C, Johann P, Reimand J, Warnatz HJ, Ryzhova M, Mack S, Ramaswamy V, Capper D, Schweizer L, Sieber L, Wittmann A, Huang Z, van Sluis P, Volckmann R, Koster J, Versteeg R, Fults D, Toledano H, Avigad S, Hoffman LM, Donson AM, Foreman N, Hewer E, Zitterbart K, Gilbert M, Armstrong TS, Gupta N, Allen JC, Karajannis MA, Zagzag D, Hasselblatt M, Kulozik AE, Witt O, Collins VP, von Hoff K, Rutkowski S, Pietsch T, Bader G, Yaspo ML, von Deimling A, Lichter P, Taylor MD, Gilbertson R, Ellison DW, Aldape K, Korshunov A, Kool M, Pfister SM. Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell. 2015;27:728-43.
  • 6. Preusser M, Berghoff AS, Manzl C, Filipits M, Weinhäusel A, Pulverer W, Dieckmann K, Widhalm G, Wöhrer A, Knosp E, Marosi C, Hainfellner JA. Clinical neuropathology practice news 1-2014: Pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastoma. Clin Neuropathol. 2014;33:6-14.
  • 7. Reifenberger G, Hentschel B, Felsberg J, Schackert G, Simon M, Schnell O, Westphal M, Wick W, Pietsch T, Loeffler M, Weller M; German Glioma Network. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int J Cancer. 2012;131:1342-50.
  • 8. Yamamura K, Kosumi K, Baba Y, Harada K, Gao F, Zhang X, Zhou L, Kitano Y, Arima K, Kaida T, Takeyama H, Higashi T, Imai K, Hashimoto D, Chikamoto A, Tan X, Baba H. LINE-1 methylation level and prognosis in pancreas cancer: Pyrosequencing technology and literature review. Surg Today. 2017;47:1450-9.
  • 9. Waha A, Koch A, Hartmann W, Mack H, Schramm J, Sörensen N, Berthold F, Wiestler OD, Pietsch T, Waha A. Analysis of HIC- 1 methylation and transcription in human ependymomas. Int J Cancer. 2004;110:542-9.
  • 10. Rousseau E, Ruchoux MM, Scaravilli F, Chapon F, Vinchon M, De Smet C, Godfraind C, Vikkula M. CDKN2A, CDKN2B and p14ARF are frequently and differentially methylated in ependymal tumours. Neuropathol Appl Neurobiol. 2003;14:574- 83.
  • 11. Koos B, Peetz-Dienhart S, Riesmeier B, Frühwald MC, Hasselblatt M. O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation is significantly less frequent in ependymal tumours as compared to malignant astrocytic gliomas. Neuropathol Appl Neurobiol. 2010;36:356-8.
  • 12. MacK SC, Taylor MD. The genetic and epigenetic basis of ependymoma. Child’s Nerv Syst. 2009;25:1195-201.
  • 13. Kim KT, Lee C-H, Chung CK, Kim JH. Is NF2 a key player of the differentially expressed gene between spinal cord ependymoma and intracranial ependymoma? World Neurosurg. 2018;118:e906-17.
  • 14. Qin S, Liu M, Niu W, Zhang CL. Dysregulation of Kruppel-like factor 4 during brain development leads to hydrocephalus in mice. Proc Natl Acad Sci U S A. 2011;108:21117-21.
  • 15. Singer BD. A practical guide to the measurement and analysis of DNA methylation. Am J Respir Cell Mol Biol. 2019;61:417-28.
  • 16. Lee CH, Chung CK, Kim CH. Genetic differences on intracranial versus spinal cord ependymal tumors: A meta-analysis of genetic researches. Eur Spine J. 2016;25:3942-51.
  • 17. Zhou C, Li J, Li Q. CDKN2A methylation in esophageal cancer: A meta-analysis. Oncotarget. 2017;8:50071-83.
  • 18. Sinha S, Chunder N, Mukherjee N, Alam N, Roy A, Roychoudhury S, Kumar Panda C. Frequent deletion and methylation in SH3GL2 and CDKN2A loci are associated with early- and late- onset breast carcinoma. Ann Surg Oncol. 2008;15:1070-80.
  • 19. Csepregi A, Ebert MP, Röcken C, Schneider-Stock R, Hoffmann J, Schulz HU, Roessner A, Malfertheiner P. Promoter methylation of CDKN2A and lack of p16 expression characterize patients with hepatocellular carcinoma. BMC Cancer. 2010;10: 317.
  • 20. Tam KW, Zhang W, Soh J, Stastny V, Chen M, Sun H, Thu K, Rios JJ, Yang C, Marconett CN, Selamat SA, Laird-Offringa IA, Taguchi A, Hanash S, Shames D, Ma X, Zhang MQ, Lam WL, Gazdar A. CDKN2A/p16 inactivation mechanisms and their relationship to smoke exposure and molecular features in non- small-cell lung cancer. J Thorac Oncol. 2013;8:1378-88.
  • 21. Sibin MK, Bhat DI, Narasingarao KVL, Lavanya C, Chetan GK. CDKN2A (p16) mRNA decreased expression is a marker of poor prognosis in malignant high-grade glioma. Tumor Biol. 2015;36:7607-14.
  • 22. Guyot A, Duchesne M, Robert S, Lia AS, Derouault P, Scaon E, Lemnos L, Salle H, Durand K, Labrousse F. Analysis of CDKN2A gene alterations in recurrent and non-recurrent meningioma. J Neurooncol. 2019;145:449-59.
  • 23. Bortolotto S, Chiadò-Piat L, Cavalla P, Bosone I, Mauro A, Schiffer D. CDKN2A/p16 in ependymomas. J Neurooncol. 2001;54:9-13.
  • 24. Nagai T, Aruga J, Minowa O, Sugimoto T, Ohno Y, Noda T, Mikoshiba K. Zic2 regulates the kinetics of neurulation. Proc Natl Acad Sci USA. 2000;97:1618-23.
  • 25. Pfister S, Schlaeger C, Mendrzyk F, Wittmann A, Benner A, Kulozik A, Scheurlen W, Radlwimmer B, Lichter P. Array-based profiling of reference-independent methylation status (aPRIMES) identifies frequent promoter methylation and consecutive downregulation of ZIC2 in pediatric medulloblastoma. Nucleic Acids Res. 2007;35:e51.
  • 26. Inaguma S, Ito H, Riku M, Ikeda H, Kasai K. Addiction of pancreatic cancer cells to zinc-finger transcription factor ZIC2. Oncotarget. 2015;6:28257-68.
  • 27. Marchini S, Poynor E, Barakat RR, Clivio L, Cinquini M, Fruscio R, Porcu L, Bussani C, D’Incalci M, Erba E, Romano M, Cattoretti G, Katsaros D, Koff A, Luzzatto L. The zinc finger gene ZIC2 has features of an oncogene and its overexpression correlates strongly with the clinical course of epithelial ovarian cancer. Clin Cancer Res. 2012;18:4313-24.
  • 28. Zhu P, Wang Y, He L, Huang G, Du Y, Zhang G, Yan X, Xia P, Ye B, Wang S, Hao L, Wu J, Fan Z. ZIC2-dependent OCT4 activation drives self-renewal of human liver cancer stem cells. J Clin Invest. 2015;125:3795-808.
  • 29. Yasunaga J, Taniguchi Y, Nosaka K, Yoshida M, Satou Y, Sakai T, Mitsuya H, Matsuoka M. Identification of aberrantly methylated genes in association with adult T-cell leukemia. Cancer Res. 2004;64:6002-9.
  • 30. Nakahara Y, Northcott PA, Li M, Kongkham PN, Smith C, Yan H, Croul S, Ra YS, Eberhart C, Huang A, Bigner D, Grajkowska W, Van Meter T, Rutka JT, Taylor MD. Genetic and epigenetic inactivation of Kruppel-like Factor 4 in medulloblastoma. Neoplasia. 2010;12:20-7.
  • 31. Wei D, Kanai M, Jia Z, Le X, Xie K. Krüppel-like factor 4 induces p27Kip1 expression in and suppresses the growth and metastasis of human pancreatic cancer cells. Cancer Res. 2008;68:4631-9.
  • 32. Zhao W, Hisamuddin IM, Nandan MO, Babbin BA, Lamb NE, Yang VW. Identification of Krüppel-like factor 4 as a potential tumor suppressor gene in colorectal cancer. Oncogene. 2004;23:395-402.
APA KANIT N, Uysal Yoca O, Erbayraktar S, Ozer E (2022). Methylation Profiling of Specific Genes in Ependymomas. , 213 - 218. 10.5146/tjpath.2021.01565
Chicago KANIT NAZ,Uysal Yoca Ozge,Erbayraktar Serhat,Ozer Erdener Methylation Profiling of Specific Genes in Ependymomas. (2022): 213 - 218. 10.5146/tjpath.2021.01565
MLA KANIT NAZ,Uysal Yoca Ozge,Erbayraktar Serhat,Ozer Erdener Methylation Profiling of Specific Genes in Ependymomas. , 2022, ss.213 - 218. 10.5146/tjpath.2021.01565
AMA KANIT N,Uysal Yoca O,Erbayraktar S,Ozer E Methylation Profiling of Specific Genes in Ependymomas. . 2022; 213 - 218. 10.5146/tjpath.2021.01565
Vancouver KANIT N,Uysal Yoca O,Erbayraktar S,Ozer E Methylation Profiling of Specific Genes in Ependymomas. . 2022; 213 - 218. 10.5146/tjpath.2021.01565
IEEE KANIT N,Uysal Yoca O,Erbayraktar S,Ozer E "Methylation Profiling of Specific Genes in Ependymomas." , ss.213 - 218, 2022. 10.5146/tjpath.2021.01565
ISNAD KANIT, NAZ vd. "Methylation Profiling of Specific Genes in Ependymomas". (2022), 213-218. https://doi.org/10.5146/tjpath.2021.01565
APA KANIT N, Uysal Yoca O, Erbayraktar S, Ozer E (2022). Methylation Profiling of Specific Genes in Ependymomas. Türk Patoloji Dergisi, 38(3), 213 - 218. 10.5146/tjpath.2021.01565
Chicago KANIT NAZ,Uysal Yoca Ozge,Erbayraktar Serhat,Ozer Erdener Methylation Profiling of Specific Genes in Ependymomas. Türk Patoloji Dergisi 38, no.3 (2022): 213 - 218. 10.5146/tjpath.2021.01565
MLA KANIT NAZ,Uysal Yoca Ozge,Erbayraktar Serhat,Ozer Erdener Methylation Profiling of Specific Genes in Ependymomas. Türk Patoloji Dergisi, vol.38, no.3, 2022, ss.213 - 218. 10.5146/tjpath.2021.01565
AMA KANIT N,Uysal Yoca O,Erbayraktar S,Ozer E Methylation Profiling of Specific Genes in Ependymomas. Türk Patoloji Dergisi. 2022; 38(3): 213 - 218. 10.5146/tjpath.2021.01565
Vancouver KANIT N,Uysal Yoca O,Erbayraktar S,Ozer E Methylation Profiling of Specific Genes in Ependymomas. Türk Patoloji Dergisi. 2022; 38(3): 213 - 218. 10.5146/tjpath.2021.01565
IEEE KANIT N,Uysal Yoca O,Erbayraktar S,Ozer E "Methylation Profiling of Specific Genes in Ependymomas." Türk Patoloji Dergisi, 38, ss.213 - 218, 2022. 10.5146/tjpath.2021.01565
ISNAD KANIT, NAZ vd. "Methylation Profiling of Specific Genes in Ependymomas". Türk Patoloji Dergisi 38/3 (2022), 213-218. https://doi.org/10.5146/tjpath.2021.01565